COVID-19 is a respiratory illness that also causes inflammation, but a third of hospitalized coronavirus patients develop dangerous blood clots as well. Scientists at Britain's Imperial College London hypothesize that the clots are a byproduct of a hormonal imbalance caused by an enzyme the coronavirus deactivates to invade cells, BBC News reports, and they are preparing a clinical trial to see if the experimental drug TRV027 can fix that imbalance. The trial, funded by the British Heart Foundation, begins next month, with about 60 patients getting either TRVO27 or a placebo.
TRVO27, made by Trevena, "works to rebalance hormones involved in blood pressure, water, and salt," BBC News says. It was originally developed to treat acute heart failure, though it failed to live up to expectations in a trial.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
A Man on the Inside: Netflix comedy leaves you with a 'warm fuzzy feeling'The Week Recommends Charming series has a 'tenderness' that will 'sneak up' on you
-
Bread & Roses: an 'extraordinarily courageous' documentaryThe Week Recommends Sahra Mani's 'powerful' film examines the lives of three Afghan women under the Taliban
-
V13: a 'marvelous and terrifying' account of the Bataclan terror trialsThe Week Recommends Emmanuel Carrère's work is 'absolutely gripping'
-
US charges Indian tycoon with bribery, fraudSpeed Read Indian billionaire Gautam Adani has been indicted by US prosecutors for his role in a $265 million scheme to secure solar energy deals
-
Boeing machinists approve contract, end strikeSpeed Read The company's largest union approved the new contract offer, ending a seven-week strike
-
US economy still strong in final preelection reportSpeed Read It grew at a solid 2.8% annual rate from July through September
-
Boeing machinists reject deal, continue strikeSpeed Read The rejection came the same day Boeing reported a $6.2 billion quarterly loss
-
Ports reopen after dockworkers halt strikeSpeed Read The 36 ports that closed this week, from Maine to Texas, will start reopening today
-
Empty-nest boomers aren't selling their big homesSpeed Read Most Americans 60 and older do not intend to move, according to a recent survey
-
Brazil accuses Musk of 'disinformation campaign'Speed Read A Brazilian Supreme Court judge has opened an inquiry into Elon Musk and X
-
Disney board fends off Peltz infiltration bidSpeed Read Disney CEO Bob Iger has defeated activist investor Nelson Peltz in a contentious proxy battle
